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Abstract
Background: According to the literature the three stone diseases, sialolithiasis (SL), urolithiasis (UL) and cholelithiasis
(CL) share comorbidities. We assess familial and spouse risks between these stone disease and compare them to
familial risks for concordant (same) stone disease.
Methods: Study population including familiar relationships was obtained from the Swedish Multigeneration Register
and stone disease patients were identified from nation-wide medical records. Standardized incidence ratios (SIRs) were
calculated for 0–83 year old offspring when their first-degree relatives were diagnosed with stone disease and the rates
were compared to individuals without a family history of stone disease. Numbers of offspring with SL were 7906, for
UL they were 170,757 and for CL they were 204,369.
Results: SIRs for concordant familial risks were 2.06 for SL, 1.94 for UL and 1.82 for CL. SIRs for SL and UL were slightly
higher for women than for men. Familial risks between stone diseases were modest. The highest risk of 1.17 was for UL
when family members were diagnosed with CL, or vice versa. The SIR for UL was 1.15 when family members were
diagnosed with SL. Familial risks among spouses were increased only for UL-CL pairs (1.10).
Conclusions: Familial risks for concordant SL were 2.06 and marginally lower for the other diseases. Familial risks
between stone diseases were low but higher than risks between spouses. The data show that familial clustering is
unique to each individual stone disease which would imply distinct disease mechanisms. The results cast doubt on the
reported comorbidities between these diseases.
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Background
Sialolithiasis (SL) is a condition where a calcified mass
(sialolith, salivary calculi or salivary stone) forms within
the ducts of salivary glands [1, 2]. The most common loca-
tion is the submandibular gland (Warton’s duct), while the
parotid gland and particularly the sublingual gland are less
frequently affected [3]. Reported incidence rates vary but
in the Danish patient records the incidence was 7.3 per
100,000 person-years based on medically confirmed cases
and doubled when unconfirmed cases were included [4].
Risk factors include infections, inflammation, diabetes and
Sjögren syndrome [5]. Literature on possible familial risk or
genetic predisposition in SL is practically non-existent [6].
Urolithiasis (UL) or urinary tract stone disease covering
stones in the kidney (nephrolithiasis), ureter or bladder is a
common disease with between 1 and 15% of people globally
affected at some point in their life with the condition and
the disease prevalence is increasing [7, 8]. Stone formation
is due to a combination of genetic and environmental fac-
tors. Risk factors include high urine calcium levels, obesity,
certain foods, some medications, calcium supplements,
hyperparathyroidism, gout, diabetes, hypertension, not
drinking enough fluids and family history [8, 9]. Cholelithia-
sis (CL) or gallstone disease is the most common of these
three and some 10 to 20% of the populations in western
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counties develop gallstones and the condition is becoming
more widespread due to the increasing prevalence of risk
factors such as obesity and physical inactivity [10, 11].
Other risk factors are female sex, high age, pregnancy, cer-
tain ethnic background, family history and genetics [10, 12].
According to X-ray microanalysis stones in SL and UL
share elemental composition and calcium salts are the main
inorganic chemical constituents [1]. In contrast, gallstones
are made of organic compounds, the most common ones
are cholesterol stones and rarer ones are bilirubin stones
[13]. Several epidemiological studies have observed comor-
bidities between these stone diseases. Case-control studies
from Taiwan found significant increases for nephrolithiasis
(odds ratio, OR 4.74) and CL (OR 2.20) in SL patients com-
pared to controls [14, 15]. A similar study from the same
source found a risk of renal stones (OR 1.68) in CL patients
[16]. A prospective US study found reciprocal risks for
renal stones and CL in the OR range of 1.2 to 1.6 in men
and women [17]. Although the above and other studies
make a case for true comorbidities among stone diseases,
surveillance bias is a vicious intervening factor which is ex-
tremely difficult to avoid or correct for in diseases for which
prior medical contacts have taken place [18].
Comorbidity for two diseases may be explained by
shared environmental or genetic factors. We have a
possibility to estimate the possible role of environ-
mental factors among spouses, and we have an ex-
cellent possibility to address the possible role of
genetic factors as we have data on all family rela-
tionships in Sweden [19]. In view of individual and
medical importance of the three stone diseases it
would be of outmost relevance to verify the possible
comorbidities in a setting where surveillance bias
might not operate. Sharing of familial risks between
the stone disease would provide a mechanistic ra-
tionale that some genetic and/or shared environmen-
tal factors would also pose an individual risk for
comorbidity. We use Swedish national health service
and family records to assess familial risks for the
three stone diseases. We assess spouse correlations
between these diseases in order to quantify the pos-
sible risks through cohabitation.
Methods
Family relationships were obtained from the Multigenera-
tion Register, containing the Swedish population in families.
‘The offspring generation’ was born after 1931 and by year
2015 oldest offspring reached age 83 years; siblings could
be defined only in the offspring generation. Stone diseases
were identified using the nationwide Swedish Hospital Dis-
charge Register (1987–2015) and the Outpatient Register
(2001–2015). The first stone diagnosis was considered and
a patient was only entered once, in order to avoid surveil-
lance bias. Only 9.6% of SL patients were later diagnosed
with UL or CL, and for UL and CL patients the proportions
with multiple stone diseases were even lower. In a separate
analysis, risks were calculated to offspring whose family
members were diagnosed with a single stone disease or
with multiple stone diseases. Information from the registers
was linked at the individual level via the national 10-digit
civic registration number. In the linked dataset, civic regis-
tration numbers were replaced with serial numbers to en-
sure anonymity. Revisions 9 (1987–1996) and 10 (1997-) of
the International Classification of Diseases were used to
identify SL, UL and CL patients.
Age-adjusted incidence rates for patients identified
from the inpatient and outpatient registers were calcu-
lated per 100,000 person years of the population. For in-
cidence trend plots only inpatient data were used as only
these data were available from 1987 to 2015.
Familial risk was considered for offspring with a stone
disease whose first-degree relatives (parent or siblings) were
diagnosed with the same (concordant) or different (discord-
ant) stone disease. Standardized incidence ratios (SIRs)
were calculated as the ratio of observed to expected num-
ber of cases. The expected numbers were calculated for all
individuals without a history of the defined stone disease,
and the rates were standardized by 5-year-age, gender,
period (5 years group), socioeconomic status and residential
area. The expected rates were derived from the present
dataset covering the Swedish population. The 95% confi-
dence interval (95%CI) of the SIR was calculated assuming
a Poisson distribution.
In order to assess environmental risk factors for familial
stone disease, we determined SIRs for spouses. The period
Table 1 Population and number of cases of SL, UL and CL in offspring and parents
SL UL CL
Offspring Parents Offspring Parents Offspring Parents
Total population 8,850,394 8,090,648 8,850,394 8,090,648 8,850,394 8,090,648
Diagnosis of events
No. of events 7906 8241 170,757 219,354 204,369 309,561
Mean age at diagnosis 43.8 ± 16.9 51.7 ± 16.8 47.8 ± 15.5 54.9 ± 16.8 47.1 ± 14.7 57.3 ± 18.2
Median age 45 52 49 55 47 58
Incidence rate per 100,000 person yearsa 4.1 3.6 94.2 90.5 111.4 120.8
aAge adjusted for European standardized population, SL sialolithiasis, UL urolithiasis, CL cholelithiasis
Hemminki et al. BMC Nephrology  (2018) 19:158 Page 2 of 7
Fig. 1 Age adjusted incidence rates (per 100,000 person years) for sialolithiasis (a), urolithiasis (b) and cholelithiasis (c) for Swedish inpatient
during 1987 to 2015
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at risk for spouses was defined to start at the birth year of
their first common child or at the first year that they were
registered as living in the same address, whichever came
first. The follow-up was terminated at stone disease diagno-
sis, death or when spouses no longer lived in the same ad-
dress [20].
The study was approved by the Regional Ethical Re-
view Board of Lund University (no. 2012/795).
Results
In Table 1 we show characteristics of the populations used.
The total Swedish population used for the study included
8.85 million individuals in the offspring generation and 8.09
million in the parental generation. Case numbers in the
two generations were around 8000 for SL, around 200,000
for UL, and 200,000 for CL in offspring and over 300,000
for CL in parents. The median ages (i.e., age at first hospital
contact) for all stone disease were in the 40s for offspring
and in the 50s for parents. Incidence rates per 100,000 per-
son years were in offspring and parents 4.1 and 3.6 for SL,
94.2 and 90.5 for UL, and 111.4 and 120.8 for CL.
Incidence trends for inpatients are shown in Fig. 1. Male
rate were higher than female rates for SL and UL but for
CL the opposite was the case. Note that the incidence in
Fig. 1 is lower for SL and UL than the rates cited in Table 1
because for these diseases a large proportion of diagnoses
originated from the outpatient register (see Methods).
Familial risks are shown in Table 2 for offspring when
their parents were diagnosed with the same (concordant)
stone disease. The overall familial risks were quite similar,
2.06 for SL, 1.94 for UL and 1.82 for CL. SIRs for SL and
UL were slightly higher for women than for men.
Discordant familial risks are shown in Table 3. The SIRs
for both sexes were increased for all stone disease pairs
with the exception of risk in SL when family members
were diagnosed with UL. The highest risk of 1.17 was for
UL when family members were diagnosed with CL, or vice
versa. The SIR UL was 1.15 when family members were
diagnosed with SL. For women 5 pairs were increased
compared to only 2 pairs for men. The SIRs were equally
high for men and women for UL-CL and CL-UL.
Familial risks were calculated to offspring whose family
members were diagnosed with a single stone disease or
with multiple stone diseases (Table 4). As the family his-
tory of multiple stone diseases was rare, the SIRs for off-
spring with a family history of a single stone disease were
essentially the same as those without specification of fam-
ily history as shown in Table 2. SIRs for UL and CL were
significantly lower for offspring with a family history of
multiple stone diseases compared to those with a family
history of a single stone disease.
Familial risks for the pairs of stone diseases among
spouses are shown in Table 5. The overall risk (1.10) was
increased only for UL-CL pairs. The SIR for SL in hus-
bands was 1.26 when wives were diagnosed with UL,
and conversely it was 1.26 for in wives when husbands
were diagnosed with SL.
Discussion
The available literature, cited in Introduction, describes
comorbidities between the three stone diseases SL, UL
and CL. However, as chronic comorbidities involve mul-
tiple medical examinations, risk estimation may be subject
to surveillance bias [18]. Comorbidities may be caused by
Table 2 Concordant familial risk of SL, UL, and CL
Men Women All
Family history O SIR 95% CI O SIR 95% CI O SIR 95% CI
SL 31 1.95 1.32 2.77 39 2.15 1.53 2.94 70 2.06 1.60 2.60
UL 19,234 1.91 1.88 1.94 11,221 1.99 1.95 2.02 30,455 1.94 1.92 1.96
CL 15,534 1.82 1.79 1.85 33,423 1.81 1.79 1.83 48,957 1.82 1.80 1.83
Bold type: 95% CI does not include 1.00
O observed number of cases, SIR standardized incidence ratio, CI confidence interval, SL sialolithiasis, UL urolithiasis, CL cholelithiasis






O SIR 95% CI O SIR 95% CI O SIR 95% CI
SL UL 398 1.04 0.94 1.15 436 1.03 0.94 1.13 834 1.04 0.97 1.11
SL CL 572 1.06 0.97 1.15 678 1.14 1.05 1.23 1250 1.10 1.04 1.16
UL SL 494 1.09 0.99 1.19 340 1.27 1.13 1.41 834 1.15 1.08 1.21
UL CL 5410 1.17 1.14 1.21 3316 1.16 1.12 1.20 8726 1.17 1.14 1.19
CL SL 267 1.03 0.91 1.16 714 1.18 1.09 1.27 981 1.14 1.07 1.21
CL UL 7379 1.17 1.14 1.20 16,445 1.17 1.15 1.19 23,824 1.17 1.16 1.19
Bold type: 95% CI does not include 1.00
O observed number of cases, SIR standardized incidence ratio, CI confidence interval; SL sialolithiasis, UL urolithiasis, CL cholelithiasis
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shared risk or susceptibility factors, and these can be also
tested in the family setting. Spouses share environmental
risk factors, which may be shared to a lesser extent also by
first-degree family members, in addition to the shared
genes. We thus wanted to approach the issue of comor-
bidity in the family setting which is not sensitive to sur-
veillance bias to the same degree as comorbidities in the
same individual. Another motivation of the present study
was the lack of literature on familial SL. Even though SL is
a rare disease we were able to identify over 8000 patients
through the nation-wide registers. The reported chemical
similarities between SL and kidney stone might implicate
similar mechanisms of stone formation. The strengths of
the study were its nation-wide scope, medical diagnostics
of stone diseases and complete family records obtained
from the Multigeneration Register essentially covering the
Swedish population over a century [19]. The limitation
was the lack of access to primary health care records.
The novel familial data on concordant SL showed a fa-
milial risk higher (2.06) than that for UL (1.94) or CL
(1.82). Female risks where somewhat higher than male risks
(2.15 vs. 1.95) which was also the case for UL but not for
CL. Concordant familial risks for UL are well documented
in the literature [9, 21–23]. Also many genes contribut-
ing to susceptibility to UL are known and these en-
code rare metabolic factors, including disturbances
in calcium and oxalate balance [24–26]. However, for
CL earlier studies were mainly based on case-control design
which may have inaccuracies in reporting of cases in family
members [27–29]. Several genes predisposing to CL
have been identified and these include variants encoding
apolipoproteins, lipid receptors and proteins involved in
cholesterol metabolism [10, 11].
Correlation between spouses was marginal although be-
tween UL and CL the SIR of 1.10 was statistically signifi-
cant. This could be explained by known risk factors, such
as obesity and physical inactivity. Such low correlations
suggest that surveillance bias may contribute to the re-
ported comorbidities. Familial risks between stone diseases
were also modest and they were not significant between SL
and UL for which the stone composition is similar [1]. The
SIR between UL and CL was 1.17, somewhat higher than
the SIR between spouses which may imply minor sharing
of genetic susceptibility. Similarly the SIRs between SL and
CL (1.10 and 1.14) were at least statistically significant.
Shared risk factors between these stone diseases could be
inflammation and diabetes. Further evidence on unique fa-
milial clustering of each stone disease was shown for risks
with family histories of a single stone disease which for UL
and CL were higher than those with family histories of mul-
tiple stone diseases. Although explaining such small fa-
milial risks between stone diseases is speculative, they
nevertheless provide another argument against shared dis-
ease mechanisms underlying the reported comorbidities.
The study covered a time span of 29 years and it is ap-
propriate to consider to what extent diagnostic modalities
and techniques might have changed over time. Diagnosis
of SL is usually made by characteristic history and physical
examination, confirmed by x-ray or by ultrasound. For UL
x-ray examination was the standard diagnostic modality in
the early period but it was replaced by computerized tom-
ography (CT) by around year 2000 as the primary modality.
For CL abdominal ultrasound and CT are the standard
diagnostic tools. In Sweden, the number of CT instruments
increased over the study period from 85 by 1989 to 200 by
2010 [30]. Undoubtedly also ultrasound technologies
have improved over the study period. However, how
improvements in diagnostic modalities might influence
Table 4 Concordant familial risk of SL, UL, and CL for
individuals with a family member diagnosed with a single or
multiple stone diseases
Family history of stone diseases O SIR 95% CI
SL Only SL 63 2.04 1.57 2.61
SL with others (UL or CL) 7 2.27 0.90 4.71
UL Only UL 28,367 1.94 1.92 1.97
UL with others (SL or CL) 2088 1.72 1.65 1.80
CL Only CL 46,157 1.82 1.81 1.84
CL with others (UL or SL) 2800 1.59 1.53 1.65
Bold type: 95% CI does not include 1.00
O observed number of cases, SIR standardized incidence ratio, CI confidence
interval, SL sialolithiasis, UL urolithiasis, CL cholelithiasis






O SIR 95% CI O SIR 95% CI O SIR 95% CI
SL UL 100 1.26 1.03 1.53 200 1.01 0.88 1.16 300 1.08 0.96 1.21
SL CL 37 0.82 0.58 1.13 69 1.20 0.93 1.51 106 1.03 0.84 1.25
UL SL 200 1.00 0.86 1.15 100 1.26 1.02 1.53 300 1.07 0.95 1.20
UL CL 9153 1.10 1.07 1.12 995 1.12 1.05 1.19 10,148 1.10 1.08 1.12
CL SL 69 1.18 0.92 1.50 37 0.81 0.57 1.11 106 1.02 0.83 1.23
CL UL 995 1.12 1.05 1.20 9153 1.10 1.08 1.13 10,148 1.10 1.08 1.13
Bold type: 95% confidence interval does not include 1.00
O observed number of cases, SIR standardized incidence ratio, CI confidence interval, SL sialolithiasis, UL urolithiasis, CL cholelithiasis
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incident patient numbers cannot be predicted because
higher precision may add new cases but remove false diag-
noses. In Fig. 1 the incident rate for CL was stable over the
period while for SL and UL the rates appeared to be declin-
ing. The interpretation of the rates is not simple because
for SL and UL a large number of patients were seen in out-
patient care and because we have no data on patients seen
in primary care.
Conclusions
The Swedish nation-wide data show high familial risks for
each of the concordant stone diseases, and for SL the re-
search findings were entirely novel. Risks between stone
diseases among spouses were low and significant only for
UL and CL. Familial risks between stone diseases were also
low but higher than risks between spouses. Our findings
show that familial clustering is unique to each stone disease
and further indicate that the underlying disease mecha-
nisms are distinct. The results cast doubt on excessive co-
morbidities between these three stone diseases.
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